Outpatient management of patients with cancer-associated pulmonary embolism (PE) may be a feasible, safe approach with low short-term rates of recurrent venous thromboembolism (VTE), major bleeding, ...

Cancer pts who have undergone major surgery or had previous VTE should continue prophylaxis with an LMWH after discharge for up to 28 days. a CNS = central nervous system, GI = gastrointestinal ...

[14] Well-documented risk factors for VTE development include surgery, trauma, immobility, cancer, increasing age, obesity, and acute medical illness, and many hospitalized patients have at least ...

A systematic review and meta-analysis estimating the differences in bleeding risks between therapeutic-dose non-vitamin K oral anticoagulants (NOACs) and single antiplatelet therapy (aspirin) found ...

After two consecutive years of 20%-plus gains, the S&P 500 kicked off 2025 with a solid January performance. Investors are hoping the S&P 500 can continue to grind higher and maintain its ...

Regeneron's 2025 outlook includes defensive capital allocation, competitive pressure on Eylea, et cetera. Click here to read ...

Dose-escalated radiation for locally advanced unresectable pancreatic cancer. This is an ASCO Meeting Abstract from the 2025 ASCO Gastrointestinal Cancers Symposium. This abstract does not include a ...

In an investigation of the risk factors for VTE in patients with cervical cancer, a research team developed an assay kit for TAT and then conducted a retrospective analysis on 177 patients with ...

EMA committee recommends extension of marketing authorisation for Janssen-Cilag’s subcutaneous Rybrevant to treat advanced EGFR-mutated NSCLC: Beerse, Belgium Tuesday, February ...

Janssen-Cilag International NV, a Johnson & Johnson company, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended an ...